| Computational Drug Discovery Methods | Lifetime | 79 | CN 7 | 99.38 |
| Receptor Mechanisms and Signaling | Lifetime | 502 | CN 9 | 98.72 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 296 | CN 10 | 98.27 |
| Protein Structure and Dynamics | Lifetime | 367 | CN 15 | 98.58 |
| Ubiquitin and proteasome pathways | Lifetime | 506 | CN 43 | 97.74 |
| Cancer Mechanisms and Therapy | Lifetime | 236 | CN 30 | 97.51 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 275 | CN 10 | 97.71 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 304 | CN 6 | 97.84 |
| Cancer-related gene regulation | Lifetime | 603 | CN 75 | 97.22 |
| Sirtuins and Resveratrol in Medicine | Lifetime | 162 | CN 19 | 96.28 |
| Click Chemistry and Applications | Lifetime | 634 | CN 70 | 96.20 |
| interferon and immune responses | Lifetime | 807 | CN 88 | 95.62 |
| Boron Compounds in Chemistry | Lifetime | 406 | CN 34 | 92.79 |
| Machine Learning in Bioinformatics | Lifetime | 720 | CN 202 | 92.16 |
| Protein Tyrosine Phosphatases | Lifetime | 583 | CN 41 | 89.99 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 694 | CN 73 | 89.51 |
| 14-3-3 protein interactions | Lifetime | 986 | CN 79 | 75.28 |
| Cancer-related gene regulation | 2021-2025 | 22 | CN 17 | 97.82 |
| Receptor Mechanisms and Signaling | 2021-2025 | 59 | CN 14 | 96.75 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 29 | CN 7 | 95.85 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 92 | CN 53 | 95.06 |
| Immune cells in cancer | 2021-2025 | 314 | CN 174 | 94.08 |
| Computational Drug Discovery Methods | 2021-2025 | 408 | CN 111 | 95.19 |
| Inflammasome and immune disorders | 2021-2025 | 187 | CN 93 | 93.22 |
| Epigenetics and DNA Methylation | 2021-2025 | 637 | CN 240 | 92.44 |
| Ubiquitin and proteasome pathways | 2021-2025 | 246 | CN 113 | 91.58 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 138 | CN 26 | 88.37 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 700 | CN 220 | 90.94 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 554 | CN 161 | 90.30 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 103 | CN 15 | 88.42 |
| Neuropeptides and Animal Physiology | 2021-2025 | 217 | CN 31 | 87.21 |
| Protein Structure and Dynamics | 2021-2025 | 420 | CN 78 | 90.06 |
| Metal complexes synthesis and properties | 2021-2025 | 485 | CN 43 | 89.86 |
| Genomics, phytochemicals, and oxidative stress | 2021-2025 | 254 | CN 82 | 85.28 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 97 | CN 4 | 82.22 |
| Magnetism in coordination complexes | 2021-2025 | 527 | CN 149 | 86.69 |
| Chemokine receptors and signaling | 2021-2025 | 161 | CN 22 | 79.90 |
| Pain Mechanisms and Treatments | 2021-2025 | 799 | CN 164 | 82.97 |
| Chemical Synthesis and Analysis | 2021-2025 | 820 | CN 283 | 81.31 |
| Cancer-related Molecular Pathways | 2021-2025 | 747 | CN 156 | 75.26 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 822 | CN 332 | 74.30 |
| Adenosine and Purinergic Signaling | 2021-2025 | 501 | CN 115 | 72.71 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 434 | CN 94 | 71.47 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 870 | CN 213 | 70.93 |
| Galectins and Cancer Biology | 2021-2025 | 893 | CN 259 | 65.31 |
| Bioactive Compounds and Antitumor Agents | 2021-2025 | 724 | CN 107 | 63.42 |
| Hereditary Neurological Disorders | 2021-2025 | 658 | CN 47 | 62.80 |
| Bioactive natural compounds | 2021-2025 | 289 | CN 120 | 59.20 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 773 | CN 271 | 58.56 |
| Fibroblast Growth Factor Research | 2021-2025 | 966 | CN 288 | 55.58 |
| Cell death mechanisms and regulation | 2021-2025 | 672 | CN 192 | 51.31 |
| 14-3-3 protein interactions | 2021-2025 | 154 | CN 33 | 49.90 |
| Redox biology and oxidative stress | 2021-2025 | 545 | CN 133 | 45.80 |
| Aldose Reductase and Taurine | 2021-2025 | 323 | CN 92 | 35.73 |
